Trial Profile
Phase II, Multicenter, Open Label, Clinical Trial of the Anti-PD1 Monoclonal Antibody Pembrolizumab (MK-3475) as Consolidation Therapy in Multiple Myeloma Patients With Residual Disease After Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms GEM-PEMBRESID
- 13 Mar 2020 Status changed from active, no longer recruiting to completed.
- 22 May 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology